CoChat
Sign Up
Cited by 184Pain Mechanisms and TreatmentsAldose Reductase and TaurinePeripheral Neuropathies and Disorders

Understanding Diabetic Neuropathy: Focus on Oxidative Stress

Open access
Pang, Lei, Lian, Xin, Liu, Huanqiu, Zhang, Yuan, Li, Qian, Cai, Yin, Ma, Haichun, Yu, Xin·2020·Oxidative Medicine and Cellular Longevity
DOI 10.1155/2020/9524635PMC PMC7422494
Open this paper in CoChat — free accountOpen PDF

Abstract

Diabetic neuropathy is one of the clinical syndromes characterized by pain and substantial morbidity primarily due to a lesion of the somatosensory nervous system. The burden of diabetic neuropathy is related not only to the complexity of diabetes but also to the poor outcomes and difficult treatment options. There is no specific treatment for diabetic neuropathy other than glycemic control and diligent foot care. Although various metabolic pathways are impaired in diabetic neuropathy, enhanced cellular oxidative stress is proposed as a common initiator. A mechanism-based treatment of diabetic neuropathy is challenging; a better understanding of the pathophysiology of diabetic neuropathy will help to develop strategies for the new and correct diagnostic procedures and personalized interventions. Thus, we review the current knowledge of the pathophysiology in diabetic neuropathy. We focus on discussing how the defects in metabolic and vascular pathways converge to enhance oxidative stress and how they produce the onset and progression of nerve injury present in diabetic neuropathy. We discuss if the mechanisms underlying neuropathy are similarly operated in type I and type II diabetes and the progression of antioxidants in treating diabetic neuropathy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2020/9524635

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 140

  1. [1]Callaghan B. C. Cheng H. T. Stables C. L. Smith A. L. Feldman E. L. Diabetic neuropathy: clinical manifestations and current treatments Lancet Neurology 2012 11 6 521 534 10.1016/S1474-4422(12)70065-0 2-s2.0-84861111124 22608666 PMC4254767 · DOI
  2. [2]Boulton A. J. Vinik A. I. Arezzo J. C. Diabetic neuropathies: a statement by the American Diabetes Association Diabetes Care 2005 28 4 956 962 10.2337/diacare.28.4.956 2-s2.0-20144389536 15793206 · DOI · Paper page
  3. [3]Little A. A. Edwards J. L. Feldman E. L. Diabetic neuropathies Practical Neurology 2007 7 2 82 92 17430872
  4. [4]Vinik A. I. Maser R. E. Mitchell B. D. Freeman R. Diabetic autonomic neuropathy Diabetes Care 2003 26 5 1553 1579 10.2337/diacare.26.5.1553 2-s2.0-0042405193 12716821 · DOI · Paper page
  5. [5]Vinik A. I. Mehrabyan A. Diabetic neuropathies The Medical Clinics of North America 2004 88 4 947 999 xi 10.1016/j.mcna.2004.04.009 2-s2.0-4143077217 15308387 · DOI
  6. [6]Tesfaye S. Chaturvedi N. Eaton S. E. Vascular risk factors and diabetic neuropathy The New England Journal of Medicine 2005 352 4 341 350 10.1056/NEJMoa032782 2-s2.0-19944433694 15673800 · DOI · Paper page
  7. [7]Brownlee M. Biochemistry and molecular cell biology of diabetic complications Nature 2001 414 6865 813 820 10.1038/414813a 2-s2.0-0035856980 11742414 · DOI · Paper page
  8. [8]Brownlee M. The pathobiology of diabetic complications: a unifying mechanism Diabetes 2005 54 6 1615 1625 10.2337/diabetes.54.6.1615 2-s2.0-20044376702 15919781 · DOI · Paper page
  9. [9]Feldman E. L. Callaghan B. C. Pop-Busui R. Diabetic neuropathy Nature Reviews Disease Primers 2019 5 1 10.1038/s41572-019-0092-1 2-s2.0-85067338512 31197153 · DOI · Paper page
  10. [11]Fernyhough P. McGavock J. Mechanisms of disease: mitochondrial dysfunction in sensory neuropathy and other complications in diabetes Handbook of Clinical Neurology 2014 126 353 377 10.1016/B978-0-444-53480-4.00027-8 2-s2.0-84921972920 25410234 · DOI
  11. [12]Ott M. Gogvadze V. Orrenius S. Zhivotovsky B. Mitochondria, oxidative stress and cell death Apoptosis 2007 12 5 913 922 10.1007/s10495-007-0756-2 2-s2.0-34247490186 17453160 · DOI
  12. [14]Guo K. Elzinga S. Eid S. Genome-wide DNA methylation profiling of human diabetic peripheral neuropathy in subjects with type 2 diabetes mellitus Epigenetics 2019 14 8 766 779 10.1080/15592294.2019.1615352 2-s2.0-85067846815 31132961 PMC6615525 · DOI
  13. [15]Chowdhury S. K. R. Smith D. R. Fernyhough P. The role of aberrant mitochondrial bioenergetics in diabetic neuropathy Neurobiology of Disease 2013 51 56 65 10.1016/j.nbd.2012.03.016 2-s2.0-84872685206 22446165 · DOI
  14. [16]Fernyhough P. Mitochondrial dysfunction in diabetic neuropathy: a series of unfortunate metabolic events Current Diabetes Reports 2015 15 11 10.1007/s11892-015-0671-9 2-s2.0-84942097760 26370700 · DOI
  15. [17]Rumora A. E. Lentz S. I. Hinder L. M. Dyslipidemia impairs mitochondrial trafficking and function in sensory neurons The FASEB Journal 2017 32 1 195 207 10.1096/fj.201700206r 2-s2.0-85040069047 28904018 PMC6191072 · DOI
  16. [18]Vincent A. M. Edwards J. L. Sadidi M. Feldman E. L. The antioxidant response as a drug target in diabetic neuropathy Current Drug Targets 2008 9 1 94 100 10.2174/138945008783431754 2-s2.0-38849162084 18220717 · DOI
  17. [19]Vincent A. M. Feldman E. L. New insights into the mechanisms of diabetic neuropathy Reviews in Endocrine & Metabolic Disorders 2004 5 3 227 236 10.1023/B:REMD.0000032411.11422.e0 2-s2.0-3142631792 15211094 · DOI
  18. [20]Vincent A. M. Russell J. W. Low P. Feldman E. L. Oxidative stress in the pathogenesis of diabetic neuropathy Endocrine Reviews 2004 25 4 612 628 10.1210/er.2003-0019 2-s2.0-4143110556 15294884 · DOI
  19. [21]Rock C. L. Jacob R. A. Bowen P. E. Update on the biological characteristics of the antioxidant Micronutrients Journal of the American Dietetic Association 1996 96 7 693 702 quiz 703-704 10.1016/S0002-8223(96)00190-3 2-s2.0-0002743175 8675913 · DOI
  20. [22]Cheeseman K. H. Slater T. F. An introduction to free radical biochemistry British Medical Bulletin 1993 49 3 481 493 10.1093/oxfordjournals.bmb.a072625 2-s2.0-0027177490 8221017 · DOI
  21. [24]Shi H. Noguchi N. Niki E. Comparative study on dynamics of antioxidative action of alpha-tocopheryl hydroquinone, ubiquinol, and alpha-tocopherol against lipid peroxidation Free Radical Biology & Medicine 1999 27 3-4 334 346 10.1016/S0891-5849(99)00053-2 2-s2.0-0032818701 10468207 · DOI
  22. [25]Levine M. Rumsey S. C. Daruwala R. Park J. B. Wang Y. Criteria and recommendations for vitamin C intake JAMA 1999 281 15 1415 1423 10.1001/jama.281.15.1415 2-s2.0-0033590959 10217058 · DOI · Paper page
  23. [26]Maritim A. C. Sanders R. A. Watkins J. B. Diabetes, oxidative stress, and antioxidants: a review Journal of Biochemical and Molecular Toxicology 2003 17 1 24 38 10.1002/jbt.10058 2-s2.0-0037253073 12616644 · DOI
  24. [27]Sloan G. Shillo P. Selvarajah D. A new look at painful diabetic neuropathy Diabetes Research and Clinical Practice 2018 144 177 191 10.1016/j.diabres.2018.08.020 2-s2.0-85053378115 30201394 · DOI
  25. [28]Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus The New England Journal of Medicine 1993 329 14 977 986 10.1056/NEJM199309303291401 2-s2.0-0027370108 8366922 · DOI · Paper page
  26. [29]UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 1998 352 9131 837 853 10.1016/S0140-6736(98)07019-6 2-s2.0-0032511583 9742976 · DOI · Paper page
  27. [30]Nathan D. M. Long-term complications of diabetes mellitus The New England Journal of Medicine 1993 328 23 1676 1685 10.1056/NEJM199306103282306 2-s2.0-0027253061 8487827 · DOI
  28. [31]Ruderman N. B. Williamson J. R. Brownlee M. Glucose and diabetic vascular disease1 The FASEB Journal 1992 6 11 2905 2914 10.1096/fasebj.6.11.1644256 1644256 · DOI
  29. [32]Clark C. M. Jr. Lee D. A. Prevention and treatment of the complications of diabetes mellitus The New England Journal of Medicine 1995 332 18 1210 1217 10.1056/NEJM199505043321807 2-s2.0-0029069447 7700316 · DOI
  30. [33]Ziyadeh F. N. The extracellular matrix in diabetic nephropathy American Journal of Kidney Diseases 1993 22 5 736 744 10.1016/S0272-6386(12)80440-9 2-s2.0-0027452124 8238022 · DOI
  31. [34]Callaghan B. C. Kerber K. A. Lisabeth L. L. Role of neurologists and diagnostic tests on the management of distal symmetric polyneuropathy JAMA Neurology 2014 71 9 1143 1149 10.1001/jamaneurol.2014.1279 2-s2.0-84907524623 25048157 PMC4266395 · DOI
  32. [35]Rosenberger D. C. Blechschmidt V. Timmerman H. Wolff A. Treede R. D. Challenges of neuropathic pain: focus on diabetic neuropathy Journal of Neural Transmission (Vienna) 2020 127 4 589 624 10.1007/s00702-020-02145-7 32036431 PMC7148276 · DOI
  33. [36]Scholz J. Broom D. C. Youn D. H. Blocking caspase activity prevents transsynaptic neuronal apoptosis and the loss of inhibition in lamina II of the dorsal horn after peripheral nerve injury The Journal of Neuroscience 2005 25 32 7317 7323 10.1523/JNEUROSCI.1526-05.2005 2-s2.0-23744437312 16093381 PMC6725303 · DOI
  34. [37]Campbell J. N. Meyer R. A. Mechanisms of neuropathic pain Neuron 2006 52 1 77 92 10.1016/j.neuron.2006.09.021 2-s2.0-33749061243 17015228 PMC1810425 · DOI · Paper page
  35. [38]May A. Chronic pain may change the structure of the brain Pain 2008 137 1 7 15 10.1016/j.pain.2008.02.034 2-s2.0-44749092515 18410991 · DOI
  36. [39]Dunnigan S. K. Ebadi H. Breiner A. Conduction slowing in diabetic sensorimotor polyneuropathy Diabetes Care 2013 36 11 3684 3690 10.2337/dc13-0746 2-s2.0-84891865699 24026550 PMC3816879 · DOI
  37. [40]Lupachyk S. Watcho P. Stavniichuk R. Shevalye H. Obrosova I. G. Endoplasmic reticulum stress plays a key role in the pathogenesis of diabetic peripheral neuropathy Diabetes 2013 62 3 944 952 10.2337/db12-0716 2-s2.0-84874415720 23364451 PMC3581201 · DOI
  38. [41]Clements R. S. Jr. Vourganti B. Kuba T. Oh S. J. Darnell B. Dietary myo-inositol intake and peripheral nerve function in diabetic neuropathy Metabolism 1979 28 4 477 483 10.1016/0026-0495(79)90060-X 2-s2.0-0018762330 262775 · DOI
  39. [42]Salway J. G. Whitehead L. Finnegan J. A. Karunanayaka A. Barnett D. Payne R. B. Effect of myo-inositol on peripheral-nerve function in diabetes Lancet 1978 2 8103 1282 1284 10.1016/s0140-6736(78)92043-3 2-s2.0-0018251751 82784 · DOI
  40. [43]Trachootham D. Lu W. Ogasawara M. A. Valle N. R. D. Huang P. Redox regulation of cell survival Antioxidants & Redox Signaling 2008 10 8 1343 1374 10.1089/ars.2007.1957 2-s2.0-51749088156 18522489 PMC2932530 · DOI · Paper page
  41. [44]Poulsen H. E. Specht E. Broedbaek K. RNA modifications by oxidation: a novel disease mechanism? Free Radical Biology & Medicine 2012 52 8 1353 1361 10.1016/j.freeradbiomed.2012.01.009 2-s2.0-84858998993 22306201 · DOI
  42. [46]Williams B. Angiotensin II, VEGF, and diabetic retinopathy Lancet 1998 351 9105 837 838 10.1016/S0140-6736(05)78974-1 2-s2.0-0032515659 9519992 · DOI
  43. [47]Callaghan B. C. Little A. A. Feldman E. L. Hughes R. A. Enhanced glucose control for preventing and treating diabetic neuropathy Cochrane Database of Systematic Reviews 2012 6 6, article CD007543 10.1002/14651858.cd007543.pub2 PMC4048127 22696371 · DOI
  44. [49]Gibbons C. H. Treatment-induced neuropathy of diabetes Current Diabetes Reports 2017 17 12 p. 127 10.1007/s11892-017-0960-6 2-s2.0-85032274565 29064042 · DOI
  45. [50]Hwang Y. T. Davies G. 'Insulin neuritis' to 'treatment-induced neuropathy of diabetes': new name, same mystery Practical Neurology 2016 16 1 53 55 10.1136/practneurol-2015-001215 2-s2.0-84954559279 26392573 · DOI
  46. [51]Pop-Busui R. Boulton A. J. M. Feldman E. L. Diabetic neuropathy: a position statement by the American Diabetes Association Diabetes Care 2016 40 1 136 154 10.2337/dc16-2042 2-s2.0-85008214484 27999003 PMC6977405 · DOI · Paper page
  47. [52]Ang L. Jaiswal M. Martin C. Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials Current Diabetes Reports 2014 14 9 p. 528 10.1007/s11892-014-0528-7 2-s2.0-84957429954 25139473 PMC5084623 · DOI
  48. [53]Martin C. L. Albers J. W. Pop-Busui R. for the DCCT/EDIC Research Group Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study Diabetes Care 2013 37 1 31 38 10.2337/dc13-2114 2-s2.0-84892425163 24356595 PMC3868000 · DOI · Paper page
  49. [55]Franklin G. M. Kahn L. B. Baxter J. Marshall J. A. Hamman R. F. Sensory neuropathy in non-insulin-dependent diabetes mellitus. The San Luis Valley Diabetes Study American Journal of Epidemiology 1990 131 4 633 643 10.1093/oxfordjournals.aje.a115547 2-s2.0-0025214483 2316495 · DOI
  50. [56]Partanen J. Niskanen L. Lehtinen J. Mervaala E. Siitonen O. Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus The New England Journal of Medicine 1995 333 2 89 94 10.1056/NEJM199507133330203 2-s2.0-0029038374 7777034 · DOI · Paper page
  51. [58]Boulton A. J. M. Knight G. Drury J. Ward J. D. The prevalence of symptomatic, diabetic neuropathy in an insulin-treated population Diabetes Care 1985 8 2 125 128 10.2337/diacare.8.2.125 2-s2.0-0021874754 3996169 · DOI
  52. [59]Fullerton B. Jeitler K. Seitz M. Horvath K. Berghold A. Siebenhofer A. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus Cochrane Database of Systematic Reviews 2014 2014 2, article CD009122 PMC6486147 24526393
  53. [60]Albers J. W. Herman W. H. Pop-Busui R. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Diabetes Care 2010 33 5 1090 1096 10.2337/dc09-1941 2-s2.0-77954966171 20150297 PMC2858182 · DOI
  54. [61]Pantalone K. M. Misra-Hebert A. D. Hobbs T. M. Effect of glycemic control on the Diabetes Complications Severity Index score and development of complications in people with newly diagnosed type 2 diabetes Journal of Diabetes 2018 10 3 192 199 10.1111/1753-0407.12613 2-s2.0-85035210376 28976724 · DOI
  55. [62]Ismail-Beigi F. Craven T. Banerji M. A. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial Lancet 2010 376 9739 419 430 10.1016/S0140-6736(10)60576-4 2-s2.0-77955585592 20594588 PMC4123233 · DOI · Paper page
  56. [64]The Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes The New England Journal of Medicine 2008 358 24 2545 2559 10.1056/NEJMoa0802743 2-s2.0-45149131667 18539917 PMC4551392 · DOI · Paper page
  57. [66]Roshandel D. DCCT/EDIC Research Group Chen Z. DNA methylation age calculators reveal association with diabetic neuropathy in type 1 diabetes Clinical Epigenetics 2020 12 1 p. 52 10.1186/s13148-020-00840-6 32248841 PMC7132894 · DOI
  58. [67]Kobayashi M. Zochodne D. W. Diabetic neuropathy and the sensory neuron: new aspects of pathogenesis and their treatment implications Journal of Diabetes Investigation 2018 9 6 1239 1254 10.1111/jdi.12833 2-s2.0-85054213454 29533535 PMC6215951 · DOI
  59. [68]Girard C. Will C. L. Peng J. Post-transcriptional spliceosomes are retained in nuclear speckles until splicing completion Nature Communications 2012 3 1, article 994 10.1038/ncomms1998 2-s2.0-84866077515 22871813 · DOI
  60. [69]Qaseem A. Wilt T. J. Kansagara D. Hemoglobin A1cTargets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: a guidance statement update from the American College of Physicians Annals of Internal Medicine 2018 168 8 569 576 10.7326/M17-0939 2-s2.0-85045955014 29507945 · DOI
  61. [70]Cameron N. E. Cotter M. A. Archibald V. Dines K. C. Maxfield E. K. Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats Diabetologia 1994 37 5 449 459 10.1007/s001250050131 2-s2.0-0028207046 8056181 · DOI
  62. [72]Nishikawa T. Edelstein D. du X. L. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage Nature 2000 404 6779 787 790 10.1038/35008121 2-s2.0-0034643340 10783895 · DOI · Paper page
  63. [73]Greene D. A. Arezzo J. C. Brown M. B. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy Neurology 1999 53 3 580 591 10.1212/WNL.53.3.580 10449124 · DOI
  64. [74]Behl T. Kaur I. Kotwani A. Implication of oxidative stress in progression of diabetic retinopathy Survey of Ophthalmology 2016 61 2 187 196 10.1016/j.survophthal.2015.06.001 2-s2.0-84959241807 26074354 · DOI
  65. [75]Forbes J. M. Coughlan M. T. Cooper M. E. Oxidative stress as a major culprit in kidney disease in diabetes Diabetes 2008 57 6 1446 1454 10.2337/db08-0057 2-s2.0-48249085391 18511445 · DOI · Paper page
  66. [76]Javed S. Petropoulos I. N. Alam U. Malik R. A. Treatment of painful diabetic neuropathy Therapeutic Advances in Chronic Disease 2014 6 1 15 28 10.1177/2040622314552071 2-s2.0-84919629929 25553239 PMC4269610 · DOI
  67. [77]Wolff S. P. Dean R. T. Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes The Biochemical Journal 1987 245 1 243 250 10.1042/bj2450243 2-s2.0-0023259759 3117042 PMC1148106 · DOI
  68. [78]Wells-Knecht K. J. Zyzak D. V. Litchfield J. E. Thorpe S. R. Baynes J. W. Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose Biochemistry 2002 34 3702 3709 7893666
  69. [79]Fu M. X. Wells-Knecht K. J. Blackledge J. A. Lyons T. J. Thorpe S. R. Baynes J. W. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction Diabetes 1994 43 5 676 683 10.2337/diab.43.5.676 2-s2.0-0028223128 8168645 · DOI
  70. [80]Chetyrkin S. Mathis M. Pedchenko V. Glucose autoxidation induces functional damage to proteins via modification of critical arginine residues Biochemistry 2011 50 27 6102 6112 10.1021/bi200757d 2-s2.0-79960008006 21661747 PMC3140462 · DOI
  71. [81]Stitt A. W. Li Y. M. Gardiner T. A. Bucala R. Archer D. B. Vlassara H. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats The American Journal of Pathology 1997 150 2 523 531 9033268 PMC1858286
  72. [83]Ramasamy R. Goldberg I. J. Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model Circulation Research 2010 106 9 1449 1458 10.1161/CIRCRESAHA.109.213447 2-s2.0-77952403264 20466987 PMC2882633 · DOI
  73. [84]Hers H. G. The mechanism of the transformation of glucose in fructose in the seminal vesicles Biochimica et Biophysica Acta 1956 22 1 202 203 10.1016/0006-3002(56)90247-5 13373872 · DOI
  74. [85]Bohren K. M. Grimshaw C. E. Gabbay K. H. Catalytic effectiveness of human aldose reductase. Critical role of C-terminal domain The Journal of Biological Chemistry 1992 267 29 20965 20970 1400412
  75. [86]Vikramadithyan R. K. Hu Y. Noh H. L. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice The Journal of Clinical Investigation 2005 115 9 2434 2443 10.1172/JCI24819 2-s2.0-24644491335 16127462 PMC1190371 · DOI
  76. [87]Stewart M. A. Sherman W. R. Kurien M. M. Moonsammy G. I. Wisgerhof M. Polyol accumulations in nervous tissue of rats with experimental diabetes and galactosaemia Journal of Neurochemistry 1967 14 11 1057 1066 10.1111/j.1471-4159.1967.tb09516.x 2-s2.0-0014146669 6058523 · DOI
  77. [88]Uehara K. Yamagishi S. I. Otsuki S. Chin S. Yagihashi S. Effects of polyol pathway hyperactivity on protein kinase C activity, nociceptive peptide expression, and neuronal structure in dorsal root ganglia in diabetic mice Diabetes 2004 53 12 3239 3247 10.2337/diabetes.53.12.3239 2-s2.0-9444233894 15561956 · DOI
  78. [89]Mayer J. H. Tomlinson D. R. Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats Diabetologia 1983 25 5 433 438 10.1007/BF00282524 2-s2.0-0021086226 6197336 · DOI
  79. [90]Finegold D. Lattimer S. A. Nolle S. Bernstein M. Greene D. A. Polyol pathway activity and myo-inositol metabolism. A suggested relationship in the pathogenesis of diabetic neuropathy Diabetes 1983 32 11 988 992 10.2337/diab.32.11.988 2-s2.0-0021067173 6416910 · DOI
  80. [91]Engerman R. L. Kern T. S. Larson M. E. Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs Diabetologia 1994 37 2 141 144 10.1007/s001250050084 2-s2.0-0027954517 8163047 · DOI
  81. [92]Demaine A. G. Polymorphisms of the aldose reductase gene and susceptibility to diabetic microvascular complications Current Medicinal Chemistry 2003 10 15 1389 1398 10.2174/0929867033457359 2-s2.0-0041809017 12871136 · DOI
  82. [93]Thamotharampillai K. Chan A. K. F. Bennetts B. Decline in neurophysiological function after 7 years in an adolescent diabetic cohort and the role of aldose reductase gene polymorphisms Diabetes Care 2006 29 9 2053 2057 10.2337/dc06-0678 2-s2.0-33845288021 16936152 · DOI
  83. [94]McClain D. A. Hexosamines as mediators of nutrient sensing and regulation in diabetes Journal of Diabetes and its Complications 2002 16 1 72 80 10.1016/S1056-8727(01)00188-X 2-s2.0-0036181947 11872372 · DOI
  84. [95]McClain D. A. Lubas W. A. Cooksey R. C. Altered glycan-dependent signaling induces insulin resistance and hyperleptinemia Proceedings of the National Academy of Sciences of the United States of America 2002 99 16 10695 10699 10.1073/pnas.152346899 2-s2.0-0036679303 12136128 PMC125016 · DOI
  85. [96]Buse M. G. Hexosamines, insulin resistance, and the complications of diabetes: current status American Journal of Physiology. Endocrinology and Metabolism 2006 290 1 E1 E8 10.1152/ajpendo.00329.2005 2-s2.0-33644873810 16339923 PMC1343508 · DOI
  86. [97]Marshall S. Bacote V. Traxinger R. R. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance The Journal of Biological Chemistry 1991 266 4706 4712 2002019
  87. [98]Du X.-L. Edelstein D. Rossetti L. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation Proceedings of the National Academy of Sciences of the United States of America 2000 97 22 12222 12226 10.1073/pnas.97.22.12222 2-s2.0-0034710891 11050244 PMC17322 · DOI
  88. [99]Kreppel L. K. Blomberg M. A. Hart G. W. Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats The Journal of Biological Chemistry 1997 272 14 9308 9315 10.1074/jbc.272.14.9308 2-s2.0-0030959555 9083067 · DOI
  89. [100]Lubas W. A. Frank D. W. Krause M. Hanover J. A. O-linked GlcNAc transferase is a conserved nucleocytoplasmic protein containing tetratricopeptide repeats The Journal of Biological Chemistry 1997 272 14 9316 9324 10.1074/jbc.272.14.9316 2-s2.0-0030944105 9083068 · DOI
  90. [101]Andreozzi F. D’Alessandris C. Federici M. Activation of the hexosamine pathway leads to phosphorylation of insulin receptor substrate-1 on Ser307 and Ser612 and impairs the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin insulin biosynthetic pathway in RIN pancreatic beta-cells Endocrinology 2004 145 6 2845 2857 10.1210/en.2003-0939 2-s2.0-2542453754 15001544 · DOI
  91. [102]Federici M. Menghini R. Mauriello A. Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells Circulation 2002 106 4 466 472 10.1161/01.CIR.0000023043.02648.51 2-s2.0-0037162342 12135947 · DOI
  92. [103]Buse M. G. Robinson K. A. Marshall B. A. Hresko R. C. Mueckler M. M. Enhanced O-GlcNAc protein modification is associated with insulin resistance in GLUT1-overexpressing muscles American Journal of Physiology. Endocrinology and Metabolism 2002 283 2 E241 E250 10.1152/ajpendo.00060.2002 12110528 · DOI
  93. [104]Buse M. G. Robinson K. A. Gettys T. W. McMahon E. G. Gulve E. A. Increased activity of the hexosamine synthesis pathway in muscles of insulin-resistant ob/ob mice The American Journal of Physiology 1997 272, 6 Part 1 E1080 E1088 10.1152/ajpendo.1997.272.6.E1080 9227455 · DOI
  94. [105]Yki-Jarvinen H. Daniels M. C. Virkamaki A. Makimattila S. DeFronzo R. A. McClain D. Increased glutamine:fructose-6-phosphate amidotransferase activity in skeletal muscle of patients with NIDDM Diabetes 1996 45 3 302 307 10.2337/diab.45.3.302 2-s2.0-0030042488 8593934 · DOI
  95. [106]Pouwels M. J. J. Span P. N. Tack C. J. Muscle uridine diphosphate-hexosamines do not decrease despite correction of hyperglycemia-induced insulin resistance in type 2 diabetes The Journal of Clinical Endocrinology and Metabolism 2002 87 11 5179 5184 10.1210/jc.2002-020440 2-s2.0-0036846535 12414889 · DOI
  96. [107]Pouwels M. J. J. Tack C. J. Span P. N. Role of hexosamines in insulin resistance and nutrient sensing in human adipose and muscle tissue The Journal of Clinical Endocrinology and Metabolism 2004 89 10 5132 5137 10.1210/jc.2004-0291 2-s2.0-6344261703 15472217 · DOI
  97. [108]Kolm-Litty V. Sauer U. Nerlich A. Lehmann R. Schleicher E. D. High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells The Journal of Clinical Investigation 1998 101 1 160 169 10.1172/JCI119875 2-s2.0-0031975643 9421478 PMC508552 · DOI
  98. [109]Inoguchi T. Battan R. Handler E. Sportsman J. R. Heath W. King G. L. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation Proceedings of the National Academy of Sciences of the United States of America 1992 89 22 11059 11063 10.1073/pnas.89.22.11059 2-s2.0-0026489335 1438315 PMC50483 · DOI
  99. [110]Shiba T. Inoguchi T. Sportsman J. R. Heath W. F. Bursell S. King G. L. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation American Journal of Physiology-Endocrinology and Metabolism 1993 265 5 E783 E793 10.1152/ajpendo.1993.265.5.e783 8238505 · DOI
  100. [111]Ahmed N. Advanced glycation endproducts--role in pathology of diabetic complications Diabetes Research and Clinical Practice 2005 67 1 3 21 10.1016/j.diabres.2004.09.004 2-s2.0-11144324314 15620429 · DOI
  101. [112]Toth C. Rong L. L. Yang C. Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy Diabetes 2008 57 4 1002 1017 10.2337/db07-0339 2-s2.0-42449157139 18039814 · DOI
  102. [113]Gallet X. Charloteaux B. Thomas A. Brasseur R. A fast method to predict protein interaction sites from sequences Journal of Molecular Biology 2000 302 4 917 926 10.1006/jmbi.2000.4092 2-s2.0-0034730415 10993732 · DOI
  103. [114]Yao D. Taguchi T. Matsumura T. High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A The Journal of Biological Chemistry 2007 282 42 31038 31045 10.1074/jbc.M704703200 2-s2.0-35649026775 17670746 · DOI
  104. [116]Goldin A. Beckman J. A. Schmidt A. M. Creager M. A. Advanced glycation end products: sparking the development of diabetic vascular injury Circulation 2006 114 6 597 605 10.1161/CIRCULATIONAHA.106.621854 2-s2.0-33746920337 16894049 · DOI · Paper page
  105. [117]Bierhaus A. Haslbeck K. M. Humpert P. M. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily The Journal of Clinical Investigation 2004 114 12 1741 1751 10.1172/JCI18058 2-s2.0-85047694774 15599399 PMC535062 · DOI
  106. [118]Abaci A. Oguzhan A. Kahraman S. Effect of diabetes mellitus on formation of coronary collateral vessels Circulation 1999 99 17 2239 2242 10.1161/01.CIR.99.17.2239 2-s2.0-0032960337 10226087 · DOI
  107. [119]Geraldes P. King G. L. Activation of protein kinase C isoforms and its impact on diabetic complications Circulation Research 2010 106 8 1319 1331 10.1161/CIRCRESAHA.110.217117 2-s2.0-77952468064 20431074 PMC2877591 · DOI
  108. [120]Pugliese G. Pricci F. Pugliese F. Mechanisms of glucose-enhanced extracellular matrix accumulation in rat glomerular mesangial cells Diabetes 1994 43 3 478 490 10.2337/diab.43.3.478 2-s2.0-0027954577 8314022 · DOI
  109. [121]Yerneni K. K. Bai W. Khan B. V. Medford R. M. Natarajan R. Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells Diabetes 1999 48 4 855 864 10.2337/diabetes.48.4.855 2-s2.0-0033037930 10102704 · DOI
  110. [122]Craven P. A. Studer R. K. Felder J. Phillips S. DeRubertis F. R. Nitric oxide inhibition of transforming growth factor-beta and collagen synthesis in mesangial cells Diabetes 1997 46 4 671 681 10.2337/diab.46.4.671 9075810 · DOI
  111. [123]Christiansen J. S. Gammelgaard J. Frandsen M. Parving H. H. Increased kidney size, glomerular filtration rate and renal plasma flow in short-term insulin-dependent diabetics Diabetologia 1981 20 4 451 456 10.1007/BF00253406 2-s2.0-0019424778 7016638 · DOI
  112. [124]Hostetter T. H. Troy J. L. Brenner B. M. Glomerular hemodynamics in experimental diabetes mellitus Kidney International 1981 19 3 410 415 10.1038/ki.1981.33 2-s2.0-0019460233 7241881 · DOI
  113. [125]Nakamura J. Kato K. Hamada Y. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats Diabetes 1999 48 10 2090 2095 10.2337/diabetes.48.10.2090 2-s2.0-0032836509 10512378 · DOI
  114. [126]Cameron N. E. Cotter M. A. Jack A. M. Basso M. D. Hohman T. C. Protein kinase C effects on nerve function, perfusion, Na(+), K(+)-ATPase activity and glutathione content in diabetic rats Diabetologia 1999 42 9 1120 1130 10.1007/s001250051280 2-s2.0-0032842640 10447525 · DOI
  115. [127]Vinik A. I. Bril V. Kempler P. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C β-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial Clinical Therapeutics 2005 27 8 1164 1180 10.1016/j.clinthera.2005.08.001 2-s2.0-25844459952 16199243 · DOI
  116. [128]Bansal D. Badhan Y. Gudala K. Schifano F. Ruboxistaurin for the treatment of diabetic peripheral neuropathy: a systematic review of randomized clinical trials Diabetes and Metabolism Journal 2013 37 5 375 384 10.4093/dmj.2013.37.5.375 2-s2.0-84887163693 24199167 PMC3816139 · DOI
  117. [129]Tavakoli M. Petropoulos I. N. Malik R. A. Corneal confocal microscopy to assess diabetic neuropathy: an eye on the foot Journal of Diabetes Science and Technology 2013 7 5 1179 1189 10.1177/193229681300700509 2-s2.0-84900524505 24124944 PMC3876361 · DOI
  118. [130]Lauria G. Cornblath D. R. Johansson O. EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy European Journal of Neurology 2005 12 10 747 758 10.1111/j.1468-1331.2005.01260.x 2-s2.0-27144432427 16190912 · DOI
  119. [131]Dabiri B. Kampusch S. Geyer S. H. High-resolution episcopic imaging for visualization of dermal arteries and nerves of the auricular cymba conchae in humans Frontiers in Neuroanatomy 2020 14 10.3389/fnana.2020.00022 PMC7236887 32477074 · DOI
  120. [133]Sanchez-Ramirez G. M. Caram-Salas N. L. Rocha-Gonzalez H. I. Benfotiamine relieves inflammatory and neuropathic pain in rats European Journal of Pharmacology 2006 530 1-2 48 53 10.1016/j.ejphar.2005.11.016 2-s2.0-29844452169 16359659 · DOI
  121. [134]Stracke H. Gaus W. Achenbach U. Federlin K. Bretzel R. G. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study Experimental and Clinical Endocrinology & Diabetes 2008 116 10 600 605 10.1055/s-2008-1065351 2-s2.0-57049178417 18473286 · DOI
  122. [135]Ziegler D. Ametov A. Barinov A. Oral treatment With -Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy: The SYDNEY 2 trial Diabetes Care 2006 29 11 2365 2370 10.2337/dc06-1216 2-s2.0-33845499323 17065669 · DOI
  123. [136]Ziegler D. Movsesyan L. Mankovsky B. Gurieva I. Abylaiuly Z. Strokov I. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients Diabetes Care 2009 32 8 1479 1484 10.2337/dc09-0545 2-s2.0-68149106189 19470838 PMC2713653 · DOI
  124. [137]Ametov A. S. Barinov A. Dyck P. J. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial Diabetes Care 2003 26 3 770 776 10.2337/diacare.26.3.770 2-s2.0-0042668303 12610036 · DOI
  125. [138]Papanas N. Ziegler D. Efficacy of α-lipoic acid in diabetic neuropathy Expert Opinion on Pharmacotherapy 2014 15 18 2721 2731 10.1517/14656566.2014.972935 2-s2.0-84910627065 25381809 · DOI
  126. [139]Negre-Salvayre A. Coatrieux C. Ingueneau C. Salvayre R. Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors British Journal of Pharmacology 2008 153 1 6 20 10.1038/sj.bjp.0707395 2-s2.0-37849013375 17643134 PMC2199390 · DOI · Paper page
  127. [140]Du X. Edelstein D. Brownlee M. Oral benfotiamine plus alpha-lipoic acid normalises complication-causing pathways in type 1 diabetes Diabetologia 2008 51 10 1930 1932 10.1007/s00125-008-1100-2 2-s2.0-51249107520 18663426 · DOI
  128. [141]Bertolotto F. Massone A. Combination of alpha lipoic acid and superoxide dismutase leads to physiological and symptomatic improvements in diabetic neuropathy Drugs in R&D 2012 12 1 29 34 10.2165/11599200-000000000-00000 2-s2.0-84858691016 22329607 PMC3586118 · DOI
  129. [142]Shakher J. Stevens M. J. Update on the management of diabetic polyneuropathies Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011 4 289 305 10.2147/DMSO.S11324 21887102 PMC3160854 · DOI
  130. [143]Yagihashi S. Yamagishi S. I. Wada Ri R. Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor Brain 2001 124 12 2448 2458 10.1093/brain/124.12.2448 11701599 · DOI
  131. [144]Kawai T. Takei I. Tokui M. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of Nɛ-carboxymethyl lysine Journal of Diabetes and its Complications 2010 24 6 424 432 10.1016/j.jdiacomp.2008.10.005 2-s2.0-78049240469 19716319 · DOI
  132. [145]Boulton A. J. M. Kempler P. Ametov A. Ziegler D. Whither pathogenetic treatments for diabetic polyneuropathy? Diabetes/Metabolism Research and Reviews 2013 29 5 327 333 10.1002/dmrr.2397 2-s2.0-84880009691 23381942 · DOI
  133. [146]Winkler G. Pal B. Nagybeganyi E. Ory I. Porochnavec M. Kempler P. Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy Arzneimittel-Forschung 1999 49 3 220 224 10.1055/s-0031-1300405 10219465 · DOI
  134. [147]Haupt E. Ledermann H. Kopcke W. Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study) International Journal of Clinical Pharmacology and Therapeutics 2005 43 2 71 77 10.5414/CPP43071 2-s2.0-14544300095 15726875 · DOI
  135. [149]Grewal A. S. Bhardwaj S. Pandita D. Lather V. Sekhon B. S. Updates on aldose reductase inhibitors for management of diabetic complications and non-diabetic diseases Mini Reviews in Medicinal Chemistry 2015 16 2 120 162 10.2174/1389557515666150909143737 26349493 · DOI
  136. [150]Cameron N. E. Tuck Z. McCabe L. Cotter M. A. Effect of the hydroxyl radical scavenger, dimethylthiourea, on peripheral nerve tissue perfusion, conduction velocity and nociception in experimental diabetes Diabetologia 2001 44 9 1161 1169 10.1007/s001250100626 2-s2.0-0034741718 11596672 · DOI · Paper page
  137. [151]Edwards J. L. Vincent A. M. Cheng H. T. Feldman E. L. Diabetic neuropathy: mechanisms to management Pharmacology & Therapeutics 2008 120 1 1 34 10.1016/j.pharmthera.2008.05.005 2-s2.0-51749110211 18616962 PMC4007052 · DOI
  138. [152]Sima A. A. F. Bril V. Nathaniel V. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil The New England Journal of Medicine 1988 319 9 548 555 10.1056/NEJM198809013190905 2-s2.0-0023748415 3136331 · DOI
  139. [153]O'Brien P. D. Sakowski S. A. Feldman E. L. Mouse models of diabetic neuropathy ILAR Journal 2014 54 3 259 272 10.1093/ilar/ilt052 2-s2.0-84897894276 24615439 PMC3962259 · DOI
  140. [154]Tappe-Theodor A. Kuner R. Studying ongoing and spontaneous pain in rodents--challenges and opportunities The European Journal of Neuroscience 2014 39 11 1881 1890 10.1111/ejn.12643 2-s2.0-84901695854 24888508 · DOI

Cited by

Sorted by citations

Authors
Pang, L., Lian, X., Liu, H., Zhang, Y., Li, Q., Cai, Y., Ma, H., & Yu, X.
Affiliations
  • First Hospital of Jilin University (CN)
  • Department of Anesthesiology, The First Hospital of Jilin University, Jilin, China
  • University of Hong Kong (HK)
Corresponding author
  • Ma, Haichun
  • Yu, Xin
ORCID
Venue
Oxidative Medicine and Cellular Longevity
Publisher
Wiley
Published
2020-08-03
Volume
2020
Pages
1-13
ISSN
  • 1942-0994 (ISSN-L)
  • 1942-0900
DOI
10.1155/2020/9524635
PMC
PMC7422494
OpenAlex
W3046395901
Cited by
184
References
13
Citations by year
2026: 21 · 2025: 39 · 2024: 45 · 2023: 40 · 2022: 24 · 2021: 15
FWCI
2.52
Type
journal article
Language
en
Open access
Licence
Locations
  • Oxidative Medicine and Cellular Longevity (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Educational Commission of Jilin Province of China (JJKH20201047KJ, JJKH20201085KJ, 81970228, 20200201321JC, 20190201061JC)
  • National Natural Science Foundation of China (JJKH20201047KJ, JJKH20201085KJ, 81970228, 20200201321JC, 20190201061JC)
  • Natural Science Foundation of Jilin Province (JJKH20201047KJ, JJKH20201085KJ, 81970228, 20200201321JC, 20190201061JC)
Topics
  • Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Aldose Reductase and Taurine
  • Health Sciences › Medicine › Neurology › Peripheral Neuropathies and Disorders
Keywords
diabetic neuropathy, oxidative stress, pathophysiology, metabolic pathways, vascular dysfunction, nerve injury, antioxidants, type 1 diabetes, type 2 diabetes, glycemic control, foot care
MeSH terms
Diabetic Neuropathies, Humans, Reactive Oxygen Species, Oxidative Stress

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review